ArticleInternational journal of surgery case reports2026
Beyond the image: achieving complete pathologic response in MSI-high metastatic colon cancer despite persistent PET activity.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microsatellite instability-high (MSI-H) colorectal cancer, presents high tumor mutational burden and is highly responsive to immune checkpoint inhibitors (ICIs). ICIs have transformed metastatic colorectal cancer (mCRC) treatment. However, the role of partial or discontinued immunotherapy and the interpretation of PET imaging in this setting remain challenging. Objective: We aim to report a case of MSI-H mCRC with liver metastasis demonstrating complete pathological response after partial immunotherapy despite persistent PET activity, highlighting integrative approaches of immunotherapy and surgery. Case presentation: A 49-year-old female with MSI-H left colon adenocarcinoma and a single liver metastasis underwent laparoscopic subtotal colectomy, followed by chemotherapy (FOLFOX plus bevacizumab) combined with pembrolizumab. Immunotherapy was discontinued after four cycles due to limited resources. PET-CT after chemotherapy showed persistent metabolic activity in liver lesions. She underwent surgical segmentectomy with negative margins. Final pathology showed no residual tumor. Discussion: Partial immunotherapy can induce profound pathological response in MSI-H mCRC. Persistent PET positivity may reflect immune-related inflammation rather than viable tumor, complicating response assessment. Combined immunotherapy and surgery improve survival in MSI-H metastatic disease. Emerging evidence supports tailored immunotherapy duration and multidisciplinary management. Conclusion: Partial immunotherapy in MSI-H metastatic colon cancer can achieve complete pathological remission despite PET persistence. Surgery remains vital for definitive response assessment and cure. Multimodal strategies integrating systemic immunotherapy and local treatment optimize outcomes for MSI-H mCRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.